Why did CVS raise its 2026 guidance?

The company raised Adjusted EPS guidance by $0.30 at both ends of the range, citing improvements in the Health Care Benefits and Pharmacy & Consumer Wellness segments. Management still expressed caution for the remainder of 2026 due to elevated cost trends and potential macro headwinds.

How much of the earnings improvement is from underlying performance versus one-time items?

Much of the year-over-year improvement reflects underlying Health Care Benefits performance, notably the Government business and a lower MBR. However, comparisons are flattered by the absence of the prior-year $448M premium deficiency reserve and $387M legacy litigation charge. Adjusted EPS, which excludes amortization and other items, also benefited from the segment margin recovery plan.

Is the Health Care Benefits margin recovery sustainable?

The company attributes the improvement to Government business execution and exiting the individual exchange business. Management kept a cautious stance on the rest of the year, and the MBR benefited from $1.1B of favorable prior-year reserve development, which may not recur at the same level, so sustainability is uncertain.

What pressures are weighing on the Health Services and Pharmacy segments?

Health Services adjusted operating income fell 7.1%, driven by client price improvements, partly offset by purchasing economics. Pharmacy & Consumer Wellness adjusted operating income fell 8.8% due to reimbursement pressure, business investments, and weaker seasonal illness and weather-related results, partly offset by Rite Aid volume.

Did cash flow improve?

Not in the quarter. Operating cash flow was $4.2B, down from $4.6B a year earlier, largely due to a smaller change in operating assets and liabilities. The company nonetheless raised its full-year operating cash flow guidance to at least $9.5B.

CVS 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed May 6, 2026. Cited figures are marked; the original filing is the authoritative source.

CVS Health reported first-quarter 2026 results that were strong on the bottom line and raised its full-year 2026 guidance.

Total revenues rose 6.2% year-over-year to $100.4 billion^a. GAAP diluted EPS was $2.30 (versus $1.41), and Adjusted EPS was $2.57 (versus $2.25). Operating income increased 38.7% to $4.68 billion, though the prior-year period included a $387 million legacy litigation charge and a $247 million Accountable Care loss that flatter the comparison.

Adjusted operating income grew 12.5% to $5.15 billion^b, driven mainly by the Health Care Benefits segment. The Health Care Benefits segment was the main driver. Its medical benefit ratio improved 270 basis points to 84.6%, reflecting better Government business performance and the absence of a prior-year $448 million premium deficiency reserve tied to the individual exchange business.

Adjusted operating income there rose 52.6% to $3.04 billion^c. Offsetting this, Health Services adjusted operating income fell 7.1% and Pharmacy & Consumer Wellness fell 8.8%, both pressured by pharmacy reimbursement and client price improvements. Operating cash flow was $4.2 billion, slightly below the prior year's $4.6 billion.

Management raised 2026 guidance: GAAP diluted EPS to $6.24^d–$6.44 (from $5.94–$6.14), Adjusted EPS to $7.30–$7.50 (from $7.00–$7.20), and operating cash flow to at least $9.5 billion (from at least $9.0 billion). Management described its outlook for the rest of the year as cautious, citing elevated medical cost trends and potential macro headwinds. This filing is an 8-K furnishing the earnings press release under Item 2.02, so the financial results are not deemed filed for Exchange Act purposes.

02—Key points

Key Highlights

Total revenues up 6.2% to $100.4B; growth across all operating segments.
Adjusted EPS of $2.57, up from $2.25; GAAP diluted EPS of $2.30, up from $1.41.
Health Care Benefits MBR improved 270 bps to 84.6%; adjusted operating income up 52.6% to $3.04B.
Prior-year $448M individual exchange premium deficiency reserve and $387M legacy litigation charge did not recur, flattering year-over-year comparisons.
Full-year 2026 guidance raised: Adjusted EPS to $7.30–$7.50, GAAP EPS to $6.24–$6.44, operating cash flow to at least $9.5B.
Health Services and Pharmacy & Consumer Wellness adjusted operating income declined 7.1% and 8.8%, respectively, on reimbursement pressure.
Medical membership fell about 1.1M year-over-year to 26.0M, reflecting the exit of the individual exchange business; $1.1B of favorable prior-year reserve development.

03—Questions

Frequently Asked Questions

Why did CVS raise its 2026 guidance?
The company raised Adjusted EPS guidance by $0.30 at both ends of the range, citing improvements in the Health Care Benefits and Pharmacy & Consumer Wellness segments. Management still expressed caution for the remainder of 2026 due to elevated cost trends and potential macro headwinds.
How much of the earnings improvement is from underlying performance versus one-time items?
Much of the year-over-year improvement reflects underlying Health Care Benefits performance, notably the Government business and a lower MBR. However, comparisons are flattered by the absence of the prior-year $448M premium deficiency reserve and $387M legacy litigation charge. Adjusted EPS, which excludes amortization and other items, also benefited from the segment margin recovery plan.
Is the Health Care Benefits margin recovery sustainable?
The company attributes the improvement to Government business execution and exiting the individual exchange business. Management kept a cautious stance on the rest of the year, and the MBR benefited from $1.1B of favorable prior-year reserve development, which may not recur at the same level, so sustainability is uncertain.
What pressures are weighing on the Health Services and Pharmacy segments?
Health Services adjusted operating income fell 7.1%, driven by client price improvements, partly offset by purchasing economics. Pharmacy & Consumer Wellness adjusted operating income fell 8.8% due to reimbursement pressure, business investments, and weaker seasonal illness and weather-related results, partly offset by Rite Aid volume.
Did cash flow improve?
Not in the quarter. Operating cash flow was $4.2B, down from $4.6B a year earlier, largely due to a smaller change in operating assets and liabilities. The company nonetheless raised its full-year operating cash flow guidance to at least $9.5B.

04—Continue

← View all 8-K filings